^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
hydrogen peroxide (KRC-01)
i
Other names: KRC-01
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Kortuc
Drug class:
Radiosensitiser
Related drugs:
9ms
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 (clinicaltrials.gov)
P1, N=70, Not yet recruiting, Kortuc, Inc. | Phase classification: P1/2 --> P1
Phase classification • Metastases
|
cisplatin • hydrogen peroxide (KRC-01)
9ms
KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer (clinicaltrials.gov)
P2, N=184, Recruiting, Institute of Cancer Research, United Kingdom | Trial completion date: Dec 2026 --> Nov 2027 | Trial primary completion date: Dec 2026 --> Nov 2027
Trial completion date • Trial primary completion date • Metastases
|
hydrogen peroxide (KRC-01)
over1year
KORTUC, a novel hydrogen peroxide‑based radiosensitizer for the enhancement of brachytherapy in patients with unresectable recurrent uterine cervical cancer. (PubMed, Oncol Lett)
Based on this finding, KORTUC with external irradiation is considered to be an optimal treatment strategy for patients with newly diagnosed LRCC this disease. Additionally, KORTUC may be an effective radiation response enhancer in multiple cancer types in which locoregional control after RT alone remains poor.
Journal
|
hydrogen peroxide (KRC-01)
over1year
Combined treatment with direct hydrogen peroxide administration and irradiation promotes an abscopal effect in mouse models (AACR 2023)
Indeed, H2O2 has been clinically developed as a radiosensitizer (development code: KRC-01)... Intratumoral H2O2 administration enhanced the abscopal effect through activating antitumor immunity by RT.
Preclinical
|
CD8 (cluster of differentiation 8)
|
hydrogen peroxide (KRC-01)
Share via
